Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 8/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406850 | 0.87 | GABBR2 (0.50) | GABBR2GABRR1GABBR1 | |
| SCHEMBL2406283 | 0.81 | GGPS1 (0.38) | GGPS1BTN3A1GABBR2GABBR1 | |
| SCHEMBL497156 | 0.74 | — | — | |
| SCHEMBL2407338 | 0.73 | GABBR2 (0.34) | GABBR2GABRR1GABBR1 | |
| SCHEMBL2407337 | 0.73 | GABBR2 (0.34) | GABBR2GABRR1GABBR1 | |
| SCHEMBL434442 | 0.72 | — | — | |
| SCHEMBL18378696 | 0.72 | GABBR2 (0.50) | GABBR2GABRR1GABBR1 | |
| SCHEMBL2487035 | 0.72 | GABBR2 (0.50) | GABBR2GABRR1GABBR1 | |
| Bromide SCHEMBL28912325 | 0.72 | GABBR2 (0.50) | GABBR2GABRR1GABBR1 | |
| SCHEMBL29008414 | 0.72 | GABBR2 (0.50) | GABBR2GABRR1GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772519-B2 | Process for preparing mono-allyl-functionalized dialkylphosphinic acids, salts and esters thereof with allylic compounds, and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-07-08 | — | — | US | disclosed |
| EP-2367835-B1 | PROCESS FOR PREPARING MONO-ALLYL-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, SALTS AND ESTERS THEREOF WITH ALLYLIC COMPOUNDS, AND THE USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-12-11 | — | — | EP | disclosed |
| EP-2367835-A1 | PROCESS FOR PREPARING MONO-ALLYL-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, SALTS AND ESTERS THEREOF WITH ALLYLIC COMPOUNDS, AND THE USE THEREOF | Clariant International Ltd. (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110213080-A1 | Process for Preparing Mono-Allyl-Functionalized Dialkylphosphinic Acids, Salts and Esters Thereof With Allylic Compounds, and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| WO-2010054722-A1 | PROCESS FOR PREPARING MONO-ALLYL-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, SALTS AND ESTERS THEREOF WITH ALLYLIC COMPOUNDS, AND THE USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213080-A1 | Process for Preparing Mono-Allyl-Functionalized Dialkylphosphinic Acids, Salts and Esters Thereof With Allylic Compounds, and the Use Thereof | AGL, ACSL3, ACSL6 | GGPS1 619/4885BTN3A1 2787/4885GABBR2 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.